Loading
Life sciences · Journal article
Anticancer Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Aim: Claspin (CLSPN), previously identified as a cisplatin-resistance driver and immunotherapy target in urothelial carcinoma, has not been characterized in pancreatic cancer, which remains poorly responsive to immune checkpoint blockade. This study aimed to determine whether CLSPN can be a target for immunotherapy in pancreatic cancer. Materials and Methods: CLSPN expression and its prognostic association were analyzed using a TCGA pancreatic adenocarcinoma cohort. CLSPN induction by cisplatin (CDDP) and oxaliplatin (L-OHP) was assessed by western blotting and quantitative RT-PCR. The antigen-specific reactivity of previously established CLSPN-specific, HLA-A*02:01-restricted TCR-T cells (clone yc3) against the pancreatic cancer cell line PANC-1 was evaluated by IFN-γ ELISPOT assay, with and without platinum pretreatment. Results: High CLSPN expression was associated with shorter overall, disease-free, disease-specific, and progression-free survival. CLSPN protein and mRNA expression were detected in pancreatic cancer cell lines. The expression of CLSPN was increased by platinum exposure. yc3 TCR-T cells specifically recognized CLSPN peptide-pulsed T2 cells and produced IFN-γ upon coculture with HLA-A*02:01+/CLSPN+ PANC-1 cells, and their reactivity was increased by platinum treatment. Conclusion: CLSPN is a platinum-inducible immunotherapy target in pancreatic cancer, and combining CLSPN-specific TCR-T cell therapy with platinum-based chemotherapy is a promising strategy for this disease.